


Vector Map: pENTR221

NAME: pENTR221
RESISTANT MARKER: Kanamycin resistant; 10 µg/ml
SOURCE: Invitrogen Life Technologies
V_TYPE: Gateway entry vector
SEQUENCING PRIMERS: M13 (-21), M13 reverse

POLYLINKER SEQUENCE:

```

CGACAAACAACAGATAAAACGAAAGGCCAGTCTTCCGACTGAGCCTTTC
GTTTTATTTGATGCCTGGCAGTTCCCTACTCTCGCGTTAACGCTAGCATG
GATGTTTTCCAGTCACGACGTTGTAAAAACGACGGCCAGTCTTAAGCTCG
GGCCCCAAATAATGATTTTTATTTGACTGATAGTGACCTGTTTCGTTGCAA
CAAATTGATGAGCAATGCTTTTTTATAATGCCAACTTGTACAAAAAAGC
AGGCT-linker-ORF-linker-ACCCAGCTTCTTGTACAAAAGTTGGC
ATTATAAGAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCACAT
CAGTCAAAAATAAAAATCATTATTTGCCATCCAGCTGATATCCCCTATAGTG
AGTCGTATTACATGGTCATAGCTGTTTCCTGGCAGCTCTGGCCCCGTGTCT
CAAAATCTCTGATGTTACATTGCACAAGATAAAAAATATATCATCATGAAC
AATAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGCC
ATATTCAACGGGAAACGTCGAGGCCGCGATTAAATTTCCA
    
```



Sequence:

```
1      ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT 60
61     GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG 120
121    CGGAAGAGCG CCCAATACGC AAACCGCCTC TCCC CGCGG TTGGCCGATT CATTAATGCA 180
181    GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATACGC 240
241    GTACCGCTAG CCAGGAAGAG TTTGTAGAAA CGCAAAAAGG CCATCCGTCG GGATGGCCTT 300
301    CTGCTTAGTT TGATGCCTGG CAGTTTATGG CGGGCGTCCT GCCCGCCACC CTCGGGGCCG 360
361    TTGCTTCACA ACGTTCAAAT CCGTCCCGCG CGGATTTGTC CTA CTACTCAGGA GAGCGTTTAC 420
421    CGACAAAACA CAGATAAAAC GAAAGGCCGA GTCTTCCGAC GTGACCTTTC GTTTTATTTC 480
481    ATGCCTGGCA GTTCCCTACT CTCGCGTTAA CGCTAGCATG GATGTTTTTC CAGTCACGAC 540
541    GTTGTA AAAAC GACGGCCAGT CTTAAGCTCG GGCCCAAAT AATGATTTTA TTTTGACTGA 600
601    TAGTGACCTG TTCGTTGCAA CAAATGTATG AGCAATGCTT TTTTATAATG CCAACTTTGT 660
661    ACAAAAACAG AGGTACCCA GCTTCTTGTG ACAAGTTGG CATTATAAGA AAGCATTGCT 720
721    TATCAATTTG TTGCAACGAA CAGGTCAC TA CAGTCAAAA TAAAATCATT ATTTGCCATC 780
781    CAGCTGATAT CCCCTATAGT GAGTCGTATT ACATGGTTCAT AGCTGTTTCC TGGCAGCTCT 840
841    GGCCCGTGTC TCAAAATCTC TGATGTTACA TTGCACAAGA TAAAAATATA TCATCATGAA 900
901    CAATAAAACA GTCTGCTTAC ATAAACAGTA ATACAAGGGG TGTATGAGC CATATTCAAC 960
961    GGGAAACGTC GAGGCCGCGA TTAAATTCCA ACATGGATGC TGATTTATAT GGGTATAAAT 1020
1021   GGGCTCGCGA TAATGTCGGG CAATCAGGTG CGACAATCTA TCGCTTGAT GGAAGCCCG 1080
1081   ATGCGCCAGA GTTGT TTTCTG AAACATGGCA AAGGTAGCCT TGCCAATGAT GTTACAGATG 1140
1141   AGATGGTCAG ACTAACTGG CTGACGGAAT TTATGCCTCT TCCGACCATC AAGCATTTTA 1200
1201   TCCGTA CTCC TGATGATGCA TGGT TACTCA CCCTGCGAT CCCC GAAAA ACAGCATTC 1260
1261   AGGTATTAGA AGAATATCCT GATTCAGGTG AAAATATTGT TGATGCGCTG GCAGTGTTC 1320
1321   TGCGCCGGTT GCATTCGATT CCTGTTTGA ATTGTCCTTT TAACAGCGAT CCGGTATTTC 1380
1381   GTCCTCGCTCA GCGCAATCA CGAATGAATA ACGGTTTGGT TGATGCGAGT GATTTTGATG 1440
1441   ACGAGCGTAA TGGCTGGCCT GTTGAACAAG TCTGAAAAGA AATGCATAAA CTTTTGCCAT 1500
1501   TCTCACCGGA TTCAGTCGTC ACTCATGGTG ATTTCTACT TGATAACCTT ATTTT TGACG 1560
1561   AGGGGAAATT AATAGGTTGT ATTGATGTTG GACGAGTCGG AATCGCAGAC CGATACCAGG 1620
1621   ATCTTGCCAT CTTATGGAAC TGCCTCGGTG AGTTTCTCC TTCATTACAG AAACGGCTTT 1680
1681   TTCAAAAATA TGGTATTGAT AATCCTGATA TGAATAAATT GCAGTTTCAT TTGATGCTCG 1740
1741   ATGAGTTTTT CTAATCAGAA TTGGTTAATT GGTGTAACA CTGGCAGAGC ATTACGCTGA 1800
1801   CTTGACGGGA CGGCGCAAGC TCATGACCAA AATCCCTTAA CGTGAGTTAC GCGTCGTTC 1860
1861   ACTGAGCGTC AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT TTTTTTCTG 1920
1921   GCGTAATCTG CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT TGT TGGCCG 1980
1981   ATCAAGAGCT ACCAACTCTT TTTCCGAAG TAACTGGCTT CAGCAGAGCG CAGATACCAA 2040
2041   ATACTGTCTT TCTAGTGTAG CCGTAGTTAG GCCACCACT CAAGAACTCT GTAGCACC GC 2100
2101   CTACATACCT CGCTCTGCTA ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC GATAAGTCGT 2160
2161   GTCTTACCGG TTTGGACTCA AGACGATAGT TACCGGATAA GGCGCAGCGG TCGGGCTGAA 2220
2221   CGGGGGGTTT GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA CTGAGATACC 2280
2281   TACAGCGTGA GCATTGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGCGG GACAGGTATC 2340
2341   CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC GCACGAGGGA GCTTCCAGGG GGAACGCCT 2400
2401   GGTATCTTTA TAGTCTGTG GGGTTTCGCC ACCTCTGACT TGAGCGTCTGA TTTTGTGAT 2460
2461   GCTCGTCAGG GGGGCGGAGC CTATGAAAA ACGCCAGCAA CGCGCCTTT TTACGGTTTC 2520
2521   TGGCCTTTTG CTGGCCTTTT GCTC 2544
```

All ORF clones are provided in Entry Vectors for the Invitrogen Gateway® cloning system. Invitrogen offers a whole range of Destination Vectors for a wide range of applications. Refer to the homepage of Invitrogen for further information on the Gateway® cloning system and related Invitrogen products at:

<http://www.invitrogen.com/content.cfm?pageid=4072>

For further information on the ORFeome Collaboration, visit their homepage at <http://www.orfeomecollaboration.org/html/index.shtml>.

For further technical information visit our homepage at: <http://www.dnaform.jp> or contact us under: ORF@dnaform.jp.